David Maag

7.5k total citations · 2 hit papers
57 papers, 4.6k citations indexed

About

David Maag is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Maag has authored 57 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 25 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Maag's work include PARP inhibition in cancer therapy (17 papers), RNA and protein synthesis mechanisms (10 papers) and Advanced Breast Cancer Therapies (8 papers). David Maag is often cited by papers focused on PARP inhibition in cancer therapy (17 papers), RNA and protein synthesis mechanisms (10 papers) and Advanced Breast Cancer Therapies (8 papers). David Maag collaborates with scholars based in United States, France and Australia. David Maag's co-authors include Jon R. Lorsch, Mikkel A. Algire, Craig E. Cameron, Weidong Zhong, Zhi Hong, Johnson Y. N. Lau, Jamie J. Arnold, Shane Crotty, Raul Andino and Christie A. Fekete and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

David Maag

57 papers receiving 4.5k citations

Hit Papers

The broad-spectrum antiviral ribonucleoside ribavirin is ... 2000 2026 2008 2017 2000 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
    2000 652 citations David Maag, Craig E. Cameron et al. profile →
  2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    2018 516 citations David Maag, Danielle Sullivan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Maag United States 27 2.7k 1.3k 514 506 482 57 4.6k
Katherine Galvin United States 18 2.3k 0.8× 874 0.7× 291 0.6× 383 0.8× 191 0.4× 29 3.3k
Suraj Peri United States 30 2.0k 0.7× 419 0.3× 541 1.1× 383 0.8× 189 0.4× 63 3.2k
Stéphan Vagner France 41 4.9k 1.8× 820 0.6× 247 0.5× 797 1.6× 143 0.3× 86 5.8k
Ulla Hansen United States 40 3.1k 1.1× 899 0.7× 310 0.6× 590 1.2× 254 0.5× 104 5.4k
Antonis E. Koromilas Canada 46 4.8k 1.7× 992 0.8× 1.3k 2.4× 841 1.7× 225 0.5× 103 6.9k
Laura Beretta United States 41 3.2k 1.2× 735 0.6× 1.4k 2.7× 1.0k 2.1× 131 0.3× 109 5.8k
Víctor Segura Spain 33 2.2k 0.8× 463 0.4× 303 0.6× 967 1.9× 185 0.4× 95 3.3k
M Riggs United States 24 2.9k 1.1× 438 0.3× 420 0.8× 507 1.0× 136 0.3× 33 3.8k
R. Cortese Italy 49 4.5k 1.6× 699 0.5× 524 1.0× 498 1.0× 167 0.3× 86 6.5k
Espen Stang Norway 37 3.8k 1.4× 967 0.7× 398 0.8× 304 0.6× 104 0.2× 80 5.8k

Countries citing papers authored by David Maag

Since Specialization
Citations

This map shows the geographic impact of David Maag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Maag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Maag more than expected).

Fields of papers citing papers by David Maag

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Maag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Maag. The network helps show where David Maag may publish in the future.

Co-authorship network of co-authors of David Maag

This figure shows the co-authorship network connecting the top 25 collaborators of David Maag. A scholar is included among the top collaborators of David Maag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Maag. David Maag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohn, Danny M., Padmalal Gurugama, Markus Magerl, et al.. (2024). CRISPR-Based Therapy for Hereditary Angioedema. New England Journal of Medicine. 392(5). 458–467. 10 indexed citations
2.
3.
4.
Camidge, D. Ross, Fedor Moiseenko, Hidehito Horinouchi, et al.. (2021). OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(10). S875–S875. 10 indexed citations
5.
Han, Hyo S., Banu Arun, Bella Kaufman, et al.. (2020). Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.. Journal of Clinical Oncology. 38(15_suppl). 1091–1091. 1 indexed citations
6.
7.
Lassman, Andrew B., Lisa Roberts-Rapp, И. А. Соколова, et al.. (2019). Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research. 25(11). 3259–3265. 25 indexed citations
8.
Mastracchio, Anthony, Chunqiu Lai, Maricel Torrent, et al.. (2019). Investigation of biaryl heterocycles as inhibitors of Wee1 kinase. Bioorganic & Medicinal Chemistry Letters. 29(12). 1481–1486. 5 indexed citations
9.
Hopkins, Todd A., Paul A. Ellis, Cherrie K. Donawho, et al.. (2018). PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Molecular Cancer Research. 17(2). 409–419. 173 indexed citations
10.
Hopkins, Todd A., Yan Shi, Luis E. Rodrı́guez, et al.. (2015). Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Molecular Cancer Research. 13(11). 1465–1477. 198 indexed citations
11.
Sweis, Ramzi F., Mikkel A. Algire, C.H. Arrowsmith, et al.. (2015). Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Medicinal Chemistry Letters. 6(6). 695–700. 48 indexed citations
12.
Maag, David, Micah J. Maxwell, Douglas A. Hardesty, et al.. (2011). Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proceedings of the National Academy of Sciences. 108(4). 1391–1396. 88 indexed citations
13.
Kim, Seyun, Sangwon F. Kim, David Maag, et al.. (2011). Amino Acid Signaling to mTOR Mediated by Inositol Polyphosphate Multikinase. Cell Metabolism. 13(2). 215–221. 113 indexed citations
14.
Liu, Xuesong, Yan Shi, David Maag, et al.. (2011). Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor. Clinical Cancer Research. 18(2). 510–523. 139 indexed citations
15.
Chakraborty, Anutosh, Michael A. Koldobskiy, Nicholas T. Bello, et al.. (2010). Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain. Cell. 143(6). 897–910. 296 indexed citations
16.
Mustafa, Asif K., Damian B. van Rossum, Randen L. Patterson, et al.. (2009). Glutamatergic regulation of serine racemase via reversal of PIP2 inhibition. Proceedings of the National Academy of Sciences. 106(8). 2921–2926. 52 indexed citations
17.
Passmore, Lori A., T.M. Schmeing, David Maag, et al.. (2007). The Eukaryotic Translation Initiation Factors eIF1 and eIF1A Induce an Open Conformation of the 40S Ribosome. Molecular Cell. 26(1). 41–50. 255 indexed citations
18.
Shin, Byung‐Sik, et al.. (2006). Intragenic Suppressor Mutations Restore GTPase and Translation Functions of a Eukaryotic Initiation Factor 5B Switch II Mutant. Molecular and Cellular Biology. 27(5). 1677–1685. 11 indexed citations
19.
Shin, Byung‐Sik, David Maag, Antonina Roll‐Mecak, et al.. (2002). Uncoupling of Initiation Factor eIF5B/IF2 GTPase and Translational Activities by Mutations that Lower Ribosome Affinity. Cell. 111(7). 1015–1025. 103 indexed citations
20.
Maag, David, Christian Castro, Zhi Hong, & Craig E. Cameron. (2001). Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin. Journal of Biological Chemistry. 276(49). 46094–46098. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine Galvin Breakdown of academic impact, for papers by Suraj Peri Breakdown of academic impact, for papers by Stéphan Vagner Breakdown of academic impact, for papers by Ulla Hansen Breakdown of academic impact, for papers by Antonis E. Koromilas Breakdown of academic impact, for papers by Laura Beretta Breakdown of academic impact, for papers by Víctor Segura Breakdown of academic impact, for papers by M Riggs Breakdown of academic impact, for papers by R. Cortese Breakdown of academic impact, for papers by Espen Stang
Rankless by CCL
2026